Ignite Creation Date:
2025-12-24 @ 7:32 PM
Ignite Modification Date:
2026-02-22 @ 5:08 PM
Study NCT ID:
NCT02643303
Status:
COMPLETED
Last Update Posted:
2022-12-02
First Post:
2015-12-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Sponsor:
Ludwig Institute for Cancer Research
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Head and Neck Squamous Cell Carcinoma | View |
| None | Breast Cancer | View |
| None | Sarcoma | View |
| None | Merkel Cell Carcinoma | View |
| None | Cutaneous T-Cell Lymphoma | View |
| None | Melanoma | View |
| None | Renal Cancer | View |
| None | Bladder Cancer | View |
| None | Prostate Cancer | View |
| None | Testicular Cancer | View |
| None | Solid Tumor | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Durvalumab | View |
| None | MEDI4736 | View |
| None | Tremelimumab | View |
| None | Poly-ICLC | View |
| None | Hiltonol® | View |
| None | Breast Cancer | View |
| None | Melanoma | View |
| None | In Situ | View |
| None | CTLA-4 Antibody | View |
| None | PD-L1 Antibody | View |
| None | TLR3 Agonist | View |
| None | CTCL | View |
| None | Imfinzi® | View |